Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02972632 · ClinicalTrials.gov registry record · Phase 4
Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder
A Phase 4 study of Major Depressive Disorder, sponsored by Takeda.
- Completed
- Registry status
- Phase 4
- Development phase
- 123
- Enrollment target
- 20
- Study locations
NCT02972632: Completed Phase 4 study of Major Depressive Disorder, sponsored by Takeda.
NCT02972632 is a Phase 4 study of Major Depressive Disorder that has completed, run by Takeda. The registered enrollment target is 123 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02972632, a Phase 4 study of Major Depressive Disorder, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 123 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the effectiveness of treatment with vortioxetine on participant goal achievement after a change in antidepressant medication for the treatment of major depressive disorder (MDD).
Primary Outcome
GAS is a tool to measure progress each participant has towards achieving their individualized goals. The standardized scoring was applied for statistical analysis. A semi-structured interview was conducted with each participant to conduct goal-setting at the outset of study. Another evaluation took place at end of study (EOS) visit to determine the level of progress at that time. The score for each goal ranged from -2 (much worse) to +2 (much better). GAS yielded a norm-based score standardized
Conditions Studied
Interventions
- DRUG Vortioxetine
Study Locations (20)
California
- ATP Clinical Research, Inc. - Costa Mesa
- ProScience Research Group - Culver City
- Behavioral Research Specialists, LLC - Glendale
- Pacific Research Partners - Oakland
- Excell Research - Oceanside
- Anderson Clinical Research - Redlands
- University Medical Group - Upland
Florida
- Suncoast Clinical Research Inc. - New Port Richey
- Behavioral Clinical Research , Inc - North Miami
- Compass Research Main - Orlando
- University of South Florida - Tampa
Illinois
- Great Lakes Clinical Trials - Chicago
- Baber Research Group - Naperville
Massachusetts
- Novex Clinical Research, LLC - New Bedford
- Coastal Research Associates, Inc. - South Weymouth
Colorado
- MCB Clinical Research Centers, LLC - Colorado Springs
Indiana
- Deaconess Clinic - Evansville
Michigan
- University of Michigan, Ann Arbor - Ann Arbor
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2018-02-06 |
| Phase | Phase 4 |
What the finished NCT02972632 record still lists
NCT02972632 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Vortioxetine is the first listed.
NCT02972632 names 20 study sites across 9 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT02972632 about?
NCT02972632 is a clinical study titled "Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder". The purpose of this study is to determine the effectiveness of treatment with vortioxetine on participant goal achievement after a change in antidepressant medication for the treatment of major depressive disorder (MDD).
What is the current status of trial NCT02972632?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 123 participants. The study started on 2016-12-22. Estimated completion is 2018-02-06.
What conditions does trial NCT02972632 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT02972632?
The interventions under investigation include: Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT02972632?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02972632 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02972632's enrollment target sits among peer trials
123 115th of 282 higher than 167 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI